Investigator’s Brochure (IB)

The Investigator’s Brochure (IB) is the compilation of clinical and nonclinical data on an investigational product that a sponsor must provide to every investigator before and during a trial, as required under ICH E6(R2) Good Clinical Practice, Section 7. Its purpose is to give investigators and other trial personnel the information they need to understand the product’s known risks and benefits, so they can make an informed judgment about trial conduct — appropriate dosing, route/frequency of administration, safety monitoring, and eligibility/exclusion decisions — without having to consult the full nonclinical and clinical data package themselves.

Operational definition

A document counts as an Investigator’s Brochure, in the ICH E6(R2) sense, if it meets both of the following:

• It compiles the physical, chemical, pharmaceutical, nonclinical (pharmacology, pharmacokinetics, toxicology), and available clinical (human) data on a specific investigational product, organized so an investigator can assess risk and benefit for the trial population.
• It is supplied by the sponsor to investigators and the reviewing IRB/IEC before the trial begins, and is kept current through the sponsor’s ongoing review-and-update obligation for as long as the product remains investigational.

A marketed product’s approved label or Summary of Product Characteristics does not, by itself, satisfy this definition when the product is being studied for a new indication, population, dose, or route — ICH E6(R2) Section 7.1 allows the approved labeling to serve in place of a full IB only when the product is approved and being studied largely within the terms of that labeling; otherwise a proper IB (or supplement) covering the new use is still required.

Purpose

ICH E6(R2) Section 7.1 frames the IB’s purpose as giving investigators and others involved in the trial the information needed to facilitate their understanding of the rationale for, and their compliance with, key protocol features — dose, dosing frequency/interval, methods of administration, and safety monitoring procedures — grounded in a clear picture of the product’s known and potential risks and benefits. It is the document that lets an investigator and the reviewing IRB/IEC judge whether a proposed trial’s risk-benefit balance is reasonable, and it underpins downstream safety assessments during the trial — for example, whether an adverse event is “unexpected” is judged against what the current IB describes, not against general product knowledge.

Required content

ICH E6(R2) sets out the IB’s structure (Section 7 and its appendix on IB content). A compliant IB should include, at minimum:

• Title page and signature/authorization — identifies the product, sponsor, edition/version, and date, and typically the person(s) responsible for the content.
• Confidentiality statement and table of contents.
• Summary — a brief overview (ideally around two pages) highlighting the significant physical, chemical, pharmaceutical, pharmacological, toxicological, pharmacokinetic, and clinical information available.
• Introduction — chemical/generic name, active ingredients, therapeutic class, and the rationale for the proposed trial(s).
• Physical, chemical, and pharmaceutical properties and formulation — description of the substance(s) and formulation, including known instability or handling precautions.
• Nonclinical studies — pharmacology, pharmacokinetics/product metabolism, and toxicology data from animal or in vitro studies, summarized with enough methodological detail (species, dose, route) for investigators to judge relevance.
• Effects in humans — pharmacokinetics/product metabolism, safety and efficacy findings from prior human studies, and any marketing experience if the product is marketed elsewhere.
• Summary of data and guidance for the investigator — an integrated discussion of the nonclinical and clinical data, with practical guidance on anticipated adverse reactions, safety monitoring, and dose-related precautions relevant to the trial(s) the IB supports.

Update and revision obligations

The IB is a living document, not a one-time submission. Under ICH E6(R2), the sponsor is responsible for reviewing and, if necessary, updating the IB at least annually, and for producing a revised IB — or a formal addendum/safety update — whenever significant new safety or other relevant information becomes available. Revised editions carry an updated version number and date, and the sponsor is responsible for ensuring the current version reaches investigators and the relevant IRBs/IECs and regulatory authorities in a timely way; investigators and institutions, for their part, are responsible for ensuring the IRB/IEC has the current IB on file per the GCP framework’s investigator obligations. Failure to keep the IB current is a recurring inspection finding, because an outdated IB undermines the “unexpected” determination used to classify adverse events for expedited safety reporting.

Worked example

A sponsor developing a novel oncology compound issues an IB summarizing animal toxicology (including a no-observed-adverse-effect-level dose), pharmacokinetic data from a completed Phase 1 study, and the adverse event profile observed so far. Midway through a Phase 2 trial, an unexpected serious hepatic adverse event is confirmed as drug-related in another ongoing trial of the same compound. The sponsor issues an IB addendum describing the new finding and updated monitoring guidance, distributes it to all participating sites and IRBs/IECs, and investigators reassess ongoing participants’ eligibility and monitoring in light of the new information — this sequence (new significant finding, prompt addendum, redistribution, site-level reassessment) is the update obligation in Section 7 functioning as intended, not a hypothetical.

Counter-example

A generic drug reformulation trial that stays entirely within the terms of an already-approved product’s labeling (same indication, population, dose range, and route) can rely on the approved package insert/Summary of Product Characteristics in place of a full IB, per the Section 7.1 allowance described above — supplying a separately branded “Investigator’s Brochure” document here would be redundant, not required. Similarly, a device that has not yet undergone any of the product-specific animal or human testing an IB compiles — for instance, an early feasibility concept summarized only in an internal engineering spec — does not yet have IB-eligible content to compile; a protocol synopsis or product description is not a substitute for the compiled clinical/nonclinical dataset an IB requires once trials begin.

Related terms

• ICH E6(R2) — the parent GCP guideline defining the IB requirement.
• ICH E6(R2) Section 5 Sponsor Obligations — the sponsor’s broader duty set, including maintaining and distributing the IB.
• Investigator Site File (ISF) — the site-level file where the current IB is retained as essential documentation.
• Principal Investigator (PI) — the trial role for whom the IB is the primary risk-benefit reference document.
• Contract Research Organization (CRO) — may be delegated IB preparation/maintenance duties under a written transfer.
• Sponsor vs. CRO — compares which party typically retains IB responsibility when duties are delegated.